The short answer is yes—starting July 1 2026, licensed dispensaries will be legal in Rhode Island, provided they comply with the new “2026 Cannabis Retail Framework” adopted by the state legislature. The framework expands the 2022 medical‑marijuana program, creates a limited adult‑use market, and sets stricter zoning, security, and product‑testing standards. Existing medical dispensaries that meet the updated licensing criteria can continue operating, while new applicants must follow the revised application process outlined in Senate Bill 673 and the Rhode Island Department of Health’s 2026 regulatory rulebook.
2026 Legislative Changes
The 2026 Cannabis Retail Framework builds on the 2022 medical‑marijuana act (R.I. Gen. Laws § 23‑5‑2) by authorizing up to 15 adult‑use dispensaries statewide. Senate Bill 673, passed in December 2025, introduces a two‑track licensing system: a “Medical‑Only” track for patients and a “Combined” track that serves both medical and adult‑use customers. New licensing fees rise from $5,000 to $12,500 annually, and applicants must submit a detailed site‑security plan, a community‑impact assessment, and proof of third‑party lab contracts as required by Regulation 2026‑01. The law also imposes a 0.8 % state excise tax on retail sales, with revenues earmarked for substance‑abuse treatment and public‑education programs.
What This Means for Dispensaries
Existing dispensaries must re‑apply by March 31 2026 to retain their licenses under the combined track; failure to do so will result in automatic revocation. The new zoning rules restrict retail locations to districts with a minimum of 1,000 residents and at least a half‑mile distance from schools, daycares, and religious venues. Compliance officers are now required to conduct quarterly inventory audits using the state’s seed‑to‑sale tracking system, which integrates with the Rhode Island Cannabis Tracking Portal. Violations—such as selling to minors or exceeding the 30‑gram daily purchase limit—carry penalties of up to $25,000 per incident and potential license suspension.
How Consumers Are Affected
Patients will continue to access medically certified products, but the combined track introduces a wider product catalog, including edibles, tinctures, and low‑THC hemp‑derived items. Adult‑use shoppers can purchase up to 2 ounces of dry flower or its equivalent per 30 days, with a mandatory identification check at the point of sale. The state‑run “Cannabis Consumer Hotline” provides real‑time information on dispensary locations, product recalls, and safety alerts. Additionally, the 2026 framework mandates clear, standardized labeling that lists cannabinoid potency, terpene profile, and any pesticide residues, thereby enhancing product transparency for all users.
Frequently Asked Questions
Can a medical‑only dispensary operate without converting to the combined track?
No. All medical‑only dispensaries must submit a combined‑track application by the March 2026 deadline; the legislature eliminated the standalone medical track to streamline oversight.
What are the zoning restrictions for new dispensary sites?
A dispensary must be situated in a residential or mixed‑use zone with at least 1,000 inhabitants, and it must maintain a minimum distance of 0.5 mile from schools, daycares, and places of worship, as stipulated in Regulation 2026‑01.
How does the state enforce product testing?
All cannabis products must undergo third‑party laboratory analysis for potency, contaminants, and pesticide levels. Test results are uploaded to the state’s tracking portal, and any batch failing to meet standards is barred from sale and subject to a $5,000 fine per violation.
Are there limits on how much a consumer can purchase?
Yes. Medical patients are limited to a 30‑gram daily supply, while adult‑use customers may purchase up to 2 ounces (≈56 grams) within any 30‑day period, consistent with the new statutory caps.
What penalties apply for non‑compliance with the 2026 rules?
Penalties range from monetary fines—up to $25,000 per infraction for sales to minors—to license suspension or revocation for repeated violations, as outlined in the Enforcement Section of Senate Bill 673.